Edition:
India

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

126.91USD
12:17am IST
Change (% chg)

$-0.62 (-0.49%)
Prev Close
$127.53
Open
$127.23
Day's High
$127.67
Day's Low
$126.83
Volume
462,620
Avg. Vol
2,038,121
52-wk High
$129.00
52-wk Low
$109.32

JNJ.N

Chart for JNJ.N

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer... (more)

Overall

Beta: 0.80
Market Cap(Mil.): $334,822.31
Shares Outstanding(Mil.): 2,710.89
Dividend: 0.80
Yield (%): 2.59

Financials

  JNJ.N Industry Sector
P/E (TTM): 20.76 29.41 30.38
EPS (TTM): 5.95 -- --
ROI: -- 13.85 13.36
ROE: -- 14.79 14.50

UPDATE 1-J&J settles drug manufacturing probe by U.S. states for $33 mln

May 24 Johnson & Johnson has agreed to pay $33 million to resolve charges by most U.S. states that it misrepresented the manufacturing practices behind Tylenol, Motrin, Benadryl and other over-the-counter drugs that were eventually recalled.

24 May 2017

J&J settles drug manufacturing probe by U.S. states for $33 million

May 24 Johnson & Johnson has agreed to pay $33 million to resolve charges by most U.S. states that it misrepresented the manufacturing practices behind several over-the-counter drugs that were eventually recalled.

24 May 2017

Janssen files suit in U.S. to block sale of Samsung Bioepis' Remicade copy

SEOUL A unit of healthcare conglomerate Johnson & Johnson filed a lawsuit to block a copy of its rheumatoid arthritis drug Remicade made by South Korea's Samsung Bioepis Co Ltd from being sold in the United States.

19 May 2017

Janssen files suit in U.S. to block sale of Samsung Bioepis' Remicade copy

SEOUL, May 19 A unit of healthcare conglomerate Johnson & Johnson filed a lawsuit to block a copy of its rheumatoid arthritis drug Remicade made by South Korea's Samsung Bioepis Co Ltd from being sold in the United States.

19 May 2017

Johnson & Johnson offers EU concessions over Actelion deal

BRUSSELS U.S. healthcare giant Johnson & Johnson has offered concessions in a bid to address EU antitrust concerns over its $30 billion bid for Swiss biotech company Actelion , the European Commission said on Thursday.

18 May 2017

Johnson & Johnson offers EU concessions over Actelion deal

BRUSSELS, May 18 U.S. healthcare giant Johnson & Johnson has offered concessions in a bid to address EU antitrust concerns over its $30 billion bid for Swiss biotech company Actelion, the European Commission said on Thursday.

18 May 2017

BRIEF-J&J says expects more than 10 new products to launch or file for regulatory approval by 2021

* J&J says expects more than 10 new products to launch or file for regulatory approval by 2021

17 May 2017

U.S. FDA warns of foot, leg amputations with J&J diabetes drug

Johnson & Johnson is required to add new warnings to its diabetes drug, Invokana, about the risk of foot and leg amputations, the U.S. Food and Drug Administration said on Tuesday.

17 May 2017

FDA warns of foot, leg amputations with J&J diabetes drug

Johnson & Johnson is required to add new warnings to its diabetes drug, Invokana, about the risk of foot and leg amputations, the U.S. Food and Drug Administration said on Tuesday.

17 May 2017

U.S. FDA warns of foot, leg amputations with J&J diabetes drug

May 16 Johnson & Johnson is required to add new warnings to its diabetes drug, Invokana, about the risk of foot and leg amputations, the U.S. Food and Drug Administration said on Tuesday.

17 May 2017

More From Around the Web

Earnings vs. Estimates